N-(2-oxaadamantan-1-yl)ureas of formula I, where R3 is H, C1-C3 alkyl, cyclohexyl or phenyl; R is -[CH2]n -Y; n is 0-15; in -[CH2]n - 0-n/3 of the methylene groups are optionally replaced by non adjacent oxygen atoms; and Y is a 3- or 4-substituted phenyl, a 3- or 4-substituted cyclohexyl, a N-substituted piperidin-4-yl, a N-substituted piperidin-3-yl, a di- or tri-fluorosubstituted phenyl, 4-chloro-3-trifluoromethylphenyl, 3-chloro-4-trifluoromethylphenyl, 4-fluoro-3-trifluoromethylphenyl, or 3-fluoro-4-trifluoromethylphenyl; have epoxide hydrolase (sEH) inhibitory activities similar to those of their N-(adamantan-1-yl)urea analogs. Thus, compounds I are useful as API for the treatment of sEH mediated diseases. Besides, in general, compounds (I) have higher water solubilities and lower melting points, what make them more promising from the point of view of pharmacokinetics and formulation.
式I的N-(2-氧杂孔莫烷-1-基)
脲,其中R3为H、C1-C3烷基、环己基或苯基;R为-[CH2]n-Y;n为0-15;在-[CH2]n-中,0-n/3的亚甲基基团可选择性地被非相邻的氧原子取代;Y为3-或4-取代苯基、3-或4-取代环己基、N-取代
哌啶-4-基、N-取代
哌啶-3-基、二
氟或三
氟取代苯基、4-
氯-3-三
氟甲基苯基、3-
氯-4-三
氟甲基苯基、4-
氟-3-三
氟甲基苯基或3-
氟-4-三
氟甲基苯基;具有环氧化酶(sEH)抑制活性,类似于其N-(孔莫烷-1-基)
脲类似物。因此,化合物I可用作治疗sEH介导疾病的A
PI。此外,一般而言,化合物(I)具有较高的
水溶性和较低的熔点,这使它们在药代动力学和配方方面更具有前景。